Ottava Robotic Surgical System

by Johnson & JohnsonUS

DeployStage 4 of 5

FDA de novo Jul 22, 2026. U.S. commercial launch underway. Pursuing additional indications.

Updated 22 Jul 2026Checked 10 Oct0 updates this week

Milestones

Next · Selective U.S. commercial launch
  1. Ottava development and clinical validation begins2019Complete.
  2. FDA de novo submission filedJan 2026Complete.
  3. FDA de novo authorization received22 Jul 2026Complete.
  4. Selective U.S. commercial launchTarget Q3 2026Current milestone.
  5. Additional surgical indications approvalTarget 2027Not yet reached.
  6. International regulatory submissionsTarget Q1 2027Not yet reached.

Most important, last 3 months

Upcoming

  1. Q3 2026Selective U.S. commercial launch (next)
  2. 2027Additional surgical indications approval
  3. Q1 2027International regulatory submissions
  4. Q2 2027CE mark approval and European market launch
  5. 2031Five-year milestone: 100+ hospital installations
Primer